# CheckMate 577 (NCT02743494)

> An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02743494
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Advanced Cancer
- Interventions: Nivolumab; Placebo
- Enrollment: 794
- Primary outcome: Disease-free Survival (DFS)

## Commentary we found

- YouTube: 67
- Podcasts: 67
- X threads: 60

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-577-nct02743494

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02743494", "email": "<work email>"}; the inbox owner confirms by the emailed link.